

# ALM IN SINGAPORE – CONTINGENCY PLANNING

Presentation to the Singapore Society of Actuaries

**4 November 2010**

STRICTLY PRIVATE AND CONFIDENTIAL

**J.P.Morgan**

This presentation was prepared exclusively for the benefit and internal use of market professionals and institutional investors to whom it is directly addressed and delivered (the "Addressee") and does not carry any right of publication or disclosure, in whole or in part, to any other party. This presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by JPMorgan. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of JPMorgan.

The information in this presentation is based upon any forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. JPMorgan's opinions and estimates constitute JPMorgan's judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business or any other entity. JPMorgan makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.

This presentation is not an offer or solicitation for the purchase or sale of any financial product, to enter into any transaction or to participate in any strategy. Nothing in this presentation constitutes a commitment by J.P. Morgan to enter into any transaction.

Nothing in this presentation should be construed as a recommendation to purchase any financial product, or to enter into any transaction, or as legal, tax, regulatory, accounting, investment or other advice. The Addressee must make an independent assessment of such matters in consultation with its own professional advisors.

JPMorgan's policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a subject company as consideration or inducement for the receipt of business or for compensation. JPMorgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.

**IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.**


JPMorgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries worldwide. Securities, syndicated loan arranging, financial advisory and other investment banking activities are performed by a combination of J.P. Morgan Securities Inc., J.P. Morgan plc, J.P. Morgan Securities Ltd. and the appropriately licensed subsidiaries of JPMorgan Chase & Co. in Asia-Pacific, and lending, derivatives and other commercial banking activities are performed by JPMorgan Chase Bank, N.A. JPMorgan deal team members may be employees of any of the foregoing entities.

**Copyright 2010 JPMorgan Chase & Co. All rights reserved.**

# What keeps Singapore actuaries (and their bankers) awake at night?





## The “*duration and yield*” challenges look familiar, the circumstances do not

- Weight of money chasing long dated SGD assets – not just life insurers
- Low but steep yield curve
  - Compared with par fund expected yields of ~5%
- The SGD asset market
  - Asset concentration / correlation issues
  - Very low credit spreads
  - The offshore credit trade-off



# Liabilities – Why this profile matters

A typical portfolio: lots of assets, not enough duration, material risk from ongoing low rates and yield curve flattening




Please note that this particular assumption set is used for illustrative purposes only.

## Credit: Local Singapore markets are crowded and correlated

### A relatively safe harbour, priced accordingly

- Singapore is also a material “currency play”, introducing a range of offshore investors to the competition for assets.
- Longer dated bonds remain hard to come by.



# Credit: Heading offshore?



Looking to offshore fixed income is relatively common – but not without risk

## Why you do:

- Credit is the asset class that punishes lack of diversification the most
- Generally more attractive credit spreads
- Relatively high correlation of USD and SGD rates
- Relatively liquid and efficient short term FX hedging market

## Why you should be careful:


- Foreign currency duration is NOT SGD duration
- High correlation  $\neq$  perfect correlation!
- Extending currency hedges has a cost / liquidity impact



## A hypothetical portfolio: relative risk for a simple portfolio

### Interest rate risk will likely dominate for long dated portfolios

- Yield curve flattening risk tends to dominate
- Low yields for relatively short dated assets and unwind of discount on premium assets
- Credit spread widening may also be a concern at a strategic level
- Regulatory reserving methods also need to (potentially) take into account the gaps between swap rates and the LTRFDR
- The starting point (capital, regulatory reserves, buffers between MCLs and best estimate reserves for par) can make a very large difference to the analysis



## Contingency Planning: the key “what ifs”

Risk identification is relatively easy, choosing how to respond is not

- Know your exposures and your tolerance
  - Yield curve flattening - how much does it hurt?
  - Relative yield curve risk (especially USD vs SGD)
  - When do you need to ask for more capital?
- Longer term – we need to consider that rates may remain at these levels
  - What does your business look like after 3 years at 3%?
- **Planning our response:**
  - Ensure have capacity for “tactical” hedging as required
  - Changes in business mix
  - Encourage your bankers to manufacture assets that make sense!



## Some broader challenges

### “What gets measured gets done”

- Realistically, how will we prioritise the ALM task
  - vs new products
  - vs IFRS 4 Phase 2 + Solvency 2
- Actuarial salaries